Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant OnabotulinumtoxinA Prior to Radical Prostatectomy in High Risk Localized Prostate Cancer
NCT07796490Phase 2Not yet recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Nov 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in prostate cancer (PCa) comparing Botox with Placebo (2 arms). Primary endpoints: Participant Accrual at 1 year, Protocol Adherence at 1 year and 3 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07796490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07796490.